Anavex Life Sciences Corp. Appoints VP Business Development and VP Strategic Planning

Geneva, Switzerland — February 07, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces that Ms. Angela Vernadaki and Dr. George Kalkanis have been appointed as Officers of the Company. Ms. Vernadaki, appointed as VP Business Development, brings more than ten years of experience in marketing, sales, business development and entrepreneurship in the…

Anavex Life Sciences Corp. Outlines its Central Nervous System (CNS) Portfolio of Novel Therapeutics

Geneva, Switzerland — February 01, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces its strategic vision for growth by discovering and developing cutting-edge drugs against neurological diseases. The Company’s innovative drug discovery and development programs have helped build a strong pipeline that targets a range of serious neurological diseases, including Alzheimer’s Disease…

Anavex Life Sciences Corp. Acquires a Portfolio of Patents and Appoints Dr. Alexandre Vamvakides as CSO and Director

Geneva, Switzerland — January 31, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces that it has acquired a portfolio of three patents and one patent application covering drug candidates indented to be further developed through commercialization targeting the areas of neurological diseases and cancer. The patents were assigned by Dr. Alexandre Vamvakides,…